Big Data, precision medicine and private insurance: A delicate balancing act
Open access
Date
2019-01-01Type
- Journal Article
ETH Bibliography
yes
Altmetrics
Abstract
In this paper, we discuss how access to health-related data by private insurers, other than affecting the interests of prospective policy-holders, can also influence their propensity to make personal data available for research purposes. We take the case of national precision medicine initiatives as an illustrative example of this possible tendency. Precision medicine pools together unprecedented amounts of genetic as well as phenotypic data. The possibility that private insurers could claim access to such rapidly accumulating biomedical Big Data or to health-related information derived from it would discourage people from enrolling in precision medicine studies. Should that be the case, the economic value of personal data for the insurance industry would end up affecting the public value of data as a scientific resource. In what follows we articulate three principles – trustworthiness, openness and evidence – to address this problem and tame its potentially harmful effects on the development of precision medicine and, more generally, on the advancement of medical science. Show more
Permanent link
https://doi.org/10.3929/ethz-b-000339817Publication status
publishedExternal links
Journal / series
Big Data & SocietyVolume
Pages / Article No.
Publisher
SAGESubject
Precision medicine; Big Data; information asymmetry; ethics; insurance; adverse selectionOrganisational unit
09614 - Vayena, Eftychia / Vayena, Eftychia
Funding
157556 - Ethics and Society in Personalised Medicine (SNF)
More
Show all metadata
ETH Bibliography
yes
Altmetrics